NCT00220805 - Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions

Macular Degeneration

Interventions

DRUG

Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified

The dose per infusion cycle was 2 g/kg body weight over 5 consecutive days (= 4 mL/kg body weight/infusion). The infusion duration was approximately 1.5 - 2 h.

DRUG

Albumin (Human) 25%, United States Pharmacopeia (USP)

Albumin (Human) 20% or 25% will be diluted with 5% glucose to a final concentration of 0.1%.

Trial Locations (7)

40219

St. Martinus-Krankenhaus, Augenabteilung, Düsseldorf

45147

Medizinische Eirnrichtungen der Universitat Essen, Klinik fur Erkrankungen des hinteren Augenabschnittes, Essen

47119

Augenklinik Tausendfensterhaus, Duisburg

50931

Medizinische Einrichtungen der Universitat zu Koln, Centrum fur Augenheilkunde, Cologne

52074

Universitatsklinikum Aachen, Augenklinik, Aachen

72076

Klininkum der Eberhard-Karls-Universitat Tubingen, Universitats-Augenklinik, Tübingen

79106

Kliniken und Polikliniken der Albert Ludwigs Universität, Freiburg im Breisgau